Analysts See $-0.39 EPS for Axovant Sciences Ltd. (AXON) as of June, 12

May 17, 2018 - By Jack Shaw

Axovant Sciences Ltd. (NASDAQ:AXON) Corporate Logo

Axovant Sciences Ltd. (NASDAQ:AXON)’s earnings report is awaited by WallStreet on June, 12, as reported by RTT. EPS of $-0.39 is 26.42 % up from 2017’s $-0.53 EPS. The stock increased 5.98% or $0.07 during the last trading session, hitting $1.24.Axovant Sciences Ltd. has volume of 448,778 shares. Since May 17, 2017 AXON has declined 90.77% and is downtrending. The stock underperformed the S&P500 by 102.32%.

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United States and Europe.The firm is worth $133.66 million. The Company’s lead product candidate, intepirdine, a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of Alzheimer??s disease; in Phase IIb clinical trial for treating dementia with Lewy bodies ; and in Phase II clinical trial for treating cait and balance in Alzheimer's disease, DLB, and Parkinson's disease dementia.Last it reported negative earnings. The firm is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM behavior disorder in patients with LBD.

Axovant Sciences Ltd. (NASDAQ:AXON) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.